Role of interferon-alfa in NHL: still controversial?

Recombinant interferon-alfa (Intron A, Roferon-A) has been under investigation as a therapeutic agent for non-Hodgkin's lymphoma (NHL) for 25 years. It has antitumor efficacy in a number of histologic subtypes but has not been accepted as a clinically useful agent by the majority of oncologists...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncology (Williston Park, N.Y.) N.Y.), 1999-08, Vol.13 (8), p.1147-59; discussion 1159-60
Hauptverfasser:	Haase-Statz, S, Smalley, R V
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Humans Interferon-alpha - administration & dosage Interferon-alpha - therapeutic use Lymphoma, B-Cell - drug therapy Lymphoma, Follicular - drug therapy Lymphoma, Non-Hodgkin - classification Lymphoma, Non-Hodgkin - drug therapy Lymphoma, T-Cell - drug therapy Randomized Controlled Trials as Topic Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!